# Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device

> **NCT06192758** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Boston Scientific Corporation** · enrollment: 36 (estimated)

## Conditions studied

- Prostate
- Cancer

## Interventions

- **DEVICE:** TheraSphere PCa

## Key facts

- **NCT ID:** NCT06192758
- **Lead sponsor:** Boston Scientific Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-04-15
- **Primary completion:** 2028-01
- **Final completion:** 2032-10
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06192758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06192758, "Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06192758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*